A seven-year retrospective study on the surveillance of hepatitis B in Laos

2018

Article référencé dans le Web of Science WOS:000430270700001

Paboriboune P., Vial Thomas, Chassagne F., Sitbounlang P., Soundala S., Bertani Stéphane, Sengmanothong D., Babin F. X., Steenkeste N., Deny P., Pineau P., Deharo Eric

International Journal of Hepatology, 2018, p. art. ID 9462475 [11 p.] ISSN 2090-3448

Objective. Lao PDR is one of the most highly endemic countries for hepatitis B in Asia and the second country for liver cancer incidence. Therefore, the follow-up of infected individuals through predictive serological markers is of utmost importance to monitor the progression of the pathology and take the decision on treatment. Methods. A retrospective-descriptive cohort study was conducted on 3,857 HBV-infected patients. Information about infection status (viral load, VL), liver function (aminotransferases), and treatments was recorded. Results. M/F sex ratio was 1.77 for a median age of 37. Patients under 37 displayed higher VL than older ones and men had higher VL than women. Initial VL ranged from <50 IU/mL to 2.5 10(13) IU/mL. Median aminotransferase values were 45.5 U/L for ALAT and 44 U/L for ASAT, ranging from <8 to >2,000 U/L. Men had higher aminotransferase than women. Globally 20% of patients received treatment (mainly immunostimulant and reverse-transcriptase inhibitors); 11% had high levels of VL and liver enzymes, but only 2% of them were treated. Conclusion. Public health decisions should be taken urgently to rationalise vaccination and provide fair access to early diagnosis and treatment; otherwise the burden of HBV-associated diseases will be overwhelming for Laos in the near future.

Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]

LAOS

Fonds IRD [F B010072740]

fdi:010072740